Coronavirus Conversations: Emergency Use Authorization, Public Trust, and Vaccines
Duke Science & Society
America/New York GMT -4 summer
Co-Hosted with the Duke University School of Law, The Petrie-Flom Center For Bioethics at Harvard University, The Stanford Law School Center for Law and the Biosciences,The Center For Innovation Policy at Duke Law, The Yale School of Public Health, The Johns Hopkins Berman Institute for Bioethics, and The Sabin Vaccine Institute.
Nine months in, the race to create a safe, effective COVID-19 vaccine is beginning to bear fruit. Several Phase 3 clinical trials are underway, and political pressure is mounting to deliver a vaccine before the end of the year. The only way to meet this deadline would be for the FDA to issue an emergency use authorization (EUA) for one of these vaccines. Observers are concerned, however, that an EUA-authorized vaccine may not be both safe and effective, and worry about the impact of a premature authorization on public trust in the FDA, any COVID vaccine issued this way, and even subsequent COVID vaccines.
Join Duke Science & Society and our esteemed panel of experts, including former FDA Commissioner, Rob Califf, and Founder and Director of the Scripps Research Translational Institute, Eric Topol, for a timely discussion of the suitability of the EUA process for a COVID vaccine, and the safety and efficacy that we can expect from vaccines authorized on an accelerated timeframe.
Arti K Rai
Emergency Use Authorization, Public Trust, and Vaccines
Previous registration necessary?
Simultaneous translation ?
Will it be recorded?
Robert M Califf, Eric Topol